Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymphoma
Shots: Shots:
- The US FDA has granted RMAT designation to Novartis’ Kymriah (tisagenlecleucel) to treat patients with r/r FL. The designation is based on P-II ELARA study evaluating the efficacy and safety of tisagenlecleucel in adult patients with r/r FL
- The RMAT designation supports the advancement of Kymriah and reflects the unmet need for patients with r/r follicular lymphoma. Novartis has developed Kymriah in collaboration with the Perelman School of Medicine at the University of Pennsylvania
- Kymriah is designed to be a one-time treatment and is the first FDA-approved CAR-T cell therapy- indicated for r/r ALL in pediatric & adult patients and r/DLBCL in adults. Novartis anticipates the US regulatory filing of Kymriah in 2021
Click here to read full press release/ article
Ref: Novartis | Image: Novartis
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com